Chris J. Packard

Research interests

Publications

• Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia

  Nature Reviews Cardiology · 2022 · 10.1038/s41569-022-00676-y

• Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

  European Heart Journal · 2021 · https://doi.org/10.1093/eurheartj/ehab551

• Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

  European Heart Journal · 2020 · https://doi.org/10.1093/eurheartj/ehz962

• Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)31942-1

• Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease

  JAMA · 2019 · https://doi.org/10.1001/jama.2018.20045

• Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

  JAMA Cardiology · 2018 · https://doi.org/10.1001/jamacardio.2018.1470

• Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

  European Heart Journal · 2017 · 10.1093/eurheartj/ehx144

• Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk

  JAMA · 2017 · 10.1001/jama.2017.11467

• Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease

  Science · 2016 · 10.1126/science.aad3517

• Lipid-Related Markers and Cardiovascular Disease Prediction

  EUR Research Repository (Erasmus University Rotterdam) · 2012 · 10.1001/jama.2012.6571

• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials

  The Lancet · 2010 · 10.1016/s0140-6736(09)61965-6

• Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies

  The Lancet · 2008 · 10.1016/s0140-6736(08)60602-9

• Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study

  The Lancet · 2007 · 10.1016/s0140-6736(07)60071-3

• Long-Term Follow-up of the West of Scotland Coronary Prevention Study

  New England Journal of Medicine · 2007 · 10.1056/nejmoa065994

• Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

  Journal of Internal Medicine · 2006 · 10.1111/j.1365-2796.2006.01616.x

• Overproduction of large VLDL particles is driven by increased liver fat content in man

  Diabetologia · 2006 · 10.1007/s00125-005-0125-z

• Elevated Alanine Aminotransferase Predicts New-Onset Type 2 Diabetes Independently of Classical Risk Factors, Metabolic Syndrome, and C-Reactive Protein in the West of Scotland Coronary Prevention Study

  Diabetes · 2004 · 10.2337/diabetes.53.11.2855

• Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study

  Circulation · 2003 · 10.1161/01.cir.0000080897.52664.94

• C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study

  Diabetes · 2002 · 10.2337/diabetes.51.5.1596

• Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

  The Lancet · 2002 · 10.1016/s0140-6736(02)11600-x

• Plasma Leptin and the Risk of Cardiovascular Disease in the West of Scotland Coronary Prevention Study (WOSCOPS)

  Circulation · 2001 · 10.1161/hc5001.101061

• Lipoprotein-Associated Phospholipase A 2 as an Independent Predictor of Coronary Heart Disease

  New England Journal of Medicine · 2000 · 10.1056/nejm200010193431603

• The design of a prospective study of pravastatin in the elderly at risk (PROSPER)

  The American Journal of Cardiology · 1999 · 10.1016/s0002-9149(99)00533-0

• Lipoprotein Heterogeneity and Apolipoprotein B Metabolism

  Arteriosclerosis Thrombosis and Vascular Biology · 1997 · 10.1161/01.atv.17.12.3542

• Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM

  Diabetologia · 1997 · 10.1007/s001250050700

Current projects

No projects listed.